-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $37

Benzinga·05/13/2026 13:49:34
Listen to the news
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $40 to $37.